Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Growth hormone replacement therapy is not associated with retinal changes.

D Blank1, M Riedl, A Reitner

  • 1Department of Medicine III, University of Vienna, Austria.

The Journal of Clinical Endocrinology and Metabolism
|February 26, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

ESE Clinical Practice Guideline on functioning and nonfunctioning pituitary adenomas in pregnancy.

European journal of endocrinology·2021
Same author

Changes in the prognostic values of modern cardiovascular biomarkers in relation to duration of diabetes mellitus.

Journal of diabetes and its complications·2021
Same author

Micro- and macrovascular function in patients suffering from primary adrenal insufficiency: a cross-sectional case-control study.

Journal of endocrinological investigation·2020
Same author

Quasi-Herglotz functions and convex optimization.

Royal Society open science·2020
Same author

GDF15 reflects beta cell function in obese patients independently of the grade of impairment of glucose metabolism.

Nutrition, metabolism, and cardiovascular diseases : NMCD·2019
Same author

[Diagnostics and treatment of acromegaly : Necessity for targeted monitoring of comorbidities].

Der Internist·2017

Growth hormone replacement therapy (GHRT) in growth hormone-deficient (GHD) patients does not appear to induce retinal changes. Long-term GHRT is safe for GHD patients, with no increased risk of retinopathy observed.

Area of Science:

  • Endocrinology
  • Ophthalmology
  • Diabetology

Background:

  • Growth hormone (GH) and related growth factors are implicated in diabetic retinopathy pathogenesis.
  • Previous reports suggested retinal changes mimicking diabetic retinopathy in GH-deficient patients on GH replacement therapy (GHRT).

Purpose of the Study:

  • To investigate whether GHRT regularly induces retinal changes in growth hormone-deficient (GHD) patients.
  • To evaluate the safety of long-term GHRT concerning retinal health.

Main Methods:

  • Ophthalmological examination of 61 GHD patients on long-term GHRT.
  • Fundus examinations performed after pupil dilation using specialized ophthalmic equipment.
  • Assessment for vascular and retinal abnormalities, including macular edema, microaneurysms, and hemorrhages.

Related Experiment Videos

Main Results:

  • No instances of vascular or retinal changes (e.g., macular edema, hemorrhages, exudates, proliferative changes) were detected in any patient.
  • Optic discs appeared normal in all examined GHD patients on GHRT.
  • Plasma insulin-like growth factor I levels increased significantly during GHRT.

Conclusions:

  • Long-term GHRT can be safely administered to GHD patients.
  • GHRT does not appear to carry an increased risk of developing retinal changes or diabetic retinopathy-like alterations.